Zalcitabine (DDC)
2′-3′-Dideoxycytidine; Hivid
Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons it is now rarely used to treat human immunodeficiency virus (HIV), and even removed from pharmacies entirely in some countries. Zalcitabine is an analog of pyrimidine. It is a derivative of the naturally existing deoxycytidine, made by replacing the hydroxyl group in position 3' with a hydrogen. It is phosphorylated in T cells and other HIV target cells into its active triphosphate form, ddCTP. This active metabolite works as a substrate for HIV reverse transcriptase, and also by incorporation into the viral DNA, hence terminating the chain elongation due to the missing hydroxyl group. Since zalcitabine is a reverse transcriptase inhibitor it possesses activity only against retroviruses.
Organism species: Pan-species (General)
- Customized Service n/a Complete Antigen of Zalcitabine (DDC) Antigenic Transformation Customized Service Offer
- Customized Service n/a Monoclonal Antibody to Zalcitabine (DDC) Monoclonal Antibody Customized Service Offer
- Customized Service n/a Polyclonal Antibody to Zalcitabine (DDC) Polyclonal Antibody Customized Service Offer
- Customized Service n/a CLIA Kit for Zalcitabine (DDC) CLIA Kit Customized Service Offer
- Customized Service n/a ELISA Kit for Zalcitabine (DDC) ELISA Kit Customized Service Offer